培美曲塞联合铂类药物一线用药治疗晚期非小细胞肺癌(NSCLC)的近期及远期疗效  

作　　者：周伟[1] 王兴远[1] 龙翔宇[1] 应伟[1] 汪建[1] 

机构地区：[1]广安市人民医院肿瘤科,四川638000

出　　处：《当代医学》2016年第11期125-127,共3页Contemporary Medicine

摘　　要：目的探讨培美曲塞联合铂类药物一线用药治疗晚期非小细胞肺癌(NSCLC)的近期及远期疗效。方法本研究选取了62例晚期非小细胞肺癌患者作为研究对象,将患者随机分为对照组和观察组,每组31例,对照组患者采用培美曲塞联合卡铂治疗,观察组患者采用培美曲塞联合顺铂治疗,对比2组患者的临床疗效。结果对照组患者的治疗总有效率为38.7%,观察组患者的治疗总有效率为32.3%,2组的近期治疗总有效率差异无统计学意义。对照组患者的中位生存期为(11.1±2.2)个月,1年生存率为48.4%;观察组患者的中位生存期为(10.9±2.0)个月,1年生存率为45.2%,2组患者的中位生存期及1年生存率相比差异无统计学意义。2组患者的恶心呕吐、贫血、白细胞减少、中性粒细胞减少、肝功能异常、皮疹不良反应发生率比较差异无统计学意义。与对照组相比,观察组患者的血小板减少发生率显著降低,差异具有统计学意义(P<0.05)。结论培美曲塞联合铂类药物一线用药治疗晚期非小细胞肺癌的近期及远期疗效较好,患者的不良反应发生率较低,且培美曲塞联合顺铂治疗患者的血小板减少发生率明显降低。Objective To study the pemetrexed combined platinum drugs first-line drug treatment of advanced non-small cell lung cancer （NSCLC）, recent and forward curative effect. Methods This study selectedl 90 cases of advanced non-small cell lung cancer patients as the research object, the patients were randomly divided into control group and observation group, 31 cases in each group, control group were treated by pemetrexed plus carboplatin treatment, the observation group were treated by pemetrexed combined cisplatin treatment, compared the clinical efficacy of two groups of patients. Results The treatment of patients with control group the total effective rate was 38.7%, the observation group of patients with treatment the total effective rate was 32.3%, two groups of the recent treatment of total effective rate of no statistical difference. Control group patients＇ median survival was （11.1±2.2） months, 1 year survival rate was 48.4%, the observation group of patients with a median surial was （10.9±2.0） months, 1 year survival rate was 45.2%, two groups of patients with a median survival and 1 year survival rate compared with no statistical difference. Two groups of patients with nausea and vomiting, anemia, leukopenia and neutropenia, abnormal liver function, skin rashes, incidence of adverse reaction no statistical difference. Compared with control group, the observation group of patients with significantly reduce the incidence of thrombocytopenia, and difference statistically difference （P〈 0.05）. Conclusion Joint platinum drug pemetrexed first-line drug treatment of advanced non-small cell lung cancer in the near future and the forward curative effect is better, in patients with a low incidence of adverse reaction, and pemetrexed combined cisplatin in the treatment of patients with significantly lower incidence of thrombocytopenia,

关 键 词：培美曲塞 铂类药物 一线用药 晚期 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]